文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

当免疫细胞“叛变”——胶质瘤中的肿瘤相关小胶质细胞/巨噬细胞。

When Immune Cells Turn Bad-Tumor-Associated Microglia/Macrophages in Glioma.

机构信息

Division of Experimental Neurosurgery, Department of Neurosurgery, University Hospital Heidelberg, INF400, 69120 Heidelberg, Germany.

出版信息

Int J Mol Sci. 2018 Feb 1;19(2):436. doi: 10.3390/ijms19020436.


DOI:10.3390/ijms19020436
PMID:29389898
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5855658/
Abstract

As a substantial part of the brain tumor microenvironment (TME), glioma-associated microglia/macrophages (GAMs) have an emerging role in tumor progression and in controlling anti-tumor immune responses. We review challenges and improvements of cell models and highlight the contribution of this highly plastic cell population to an immunosuppressive TME, besides their well-known functional role regarding glioma cell invasion and angiogenesis. Finally, we summarize first therapeutic interventions to target GAMs and their effect on the immunobiology of gliomas, focusing on their interaction with T cells.

摘要

作为脑肿瘤微环境(TME)的重要组成部分,神经胶质瘤相关的小胶质细胞/巨噬细胞(GAMs)在肿瘤进展和控制抗肿瘤免疫反应中具有重要作用。我们综述了细胞模型的挑战和改进,并强调了这种高度可塑性细胞群体对免疫抑制性 TME 的贡献,除了它们在神经胶质瘤细胞浸润和血管生成方面的众所周知的功能作用。最后,我们总结了靶向 GAMs 的首次治疗干预及其对神经胶质瘤免疫生物学的影响,重点关注它们与 T 细胞的相互作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9320/5855658/edd0b7e73ab0/ijms-19-00436-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9320/5855658/202b330be4a4/ijms-19-00436-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9320/5855658/5f4d60909658/ijms-19-00436-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9320/5855658/edd0b7e73ab0/ijms-19-00436-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9320/5855658/202b330be4a4/ijms-19-00436-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9320/5855658/5f4d60909658/ijms-19-00436-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9320/5855658/edd0b7e73ab0/ijms-19-00436-g003.jpg

相似文献

[1]
When Immune Cells Turn Bad-Tumor-Associated Microglia/Macrophages in Glioma.

Int J Mol Sci. 2018-2-1

[2]
Role of myeloid cells in the immunosuppressive microenvironment in gliomas.

Immunobiology. 2020-1

[3]
Molecular interactions between tumor and its microenvironment in malignant gliomas.

Postepy Biochem. 2018-10-15

[4]
[The immunosuppressive microenvironment of malignant gliomas].

Arkh Patol. 2015

[5]
Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas.

Brain Pathol. 2019-1-15

[6]
CD38 deficiency in the tumor microenvironment attenuates glioma progression and modulates features of tumor-associated microglia/macrophages.

Neuro Oncol. 2012-6-14

[7]
The controversial role of microglia in malignant gliomas.

Clin Dev Immunol. 2013

[8]
Microglia and macrophages in malignant gliomas: recent discoveries and implications for promising therapies.

Clin Dev Immunol. 2013

[9]
Increased expression of stress inducible protein 1 in glioma-associated microglia/macrophages.

J Neuroimmunol. 2014-6-27

[10]
Immune microenvironment of gliomas.

Lab Invest. 2017-3-13

引用本文的文献

[1]
Progenitor cells, microglia, and non-coding RNAs: Orchestrators of glioblastoma pathogenesis and therapeutic resistance.

Noncoding RNA Res. 2025-8-5

[2]
Immune factors and their role in tumor aggressiveness in glioblastoma: Atypical cadherin FAT1 as a promising target for combating immune evasion.

Cell Mol Biol Lett. 2025-7-25

[3]
Advances in Cellular Immune Theranostic Approaches for Glioblastoma: Current Trends and Future Directions.

Cancer Innov. 2025-7-3

[4]
The prognostic significance of the NMD core factor UPF1 in low-grade glioma.

Sci Rep. 2025-7-1

[5]
Click on Click: Click-Flavone Glycosides Encapsulated in Click-Functionalised Polymersomes for Glioblastoma Therapy.

Pharmaceutics. 2025-6-12

[6]
Development and validation of liquid-liquid phase separation-associated prognostic biomarkers in gastric cancer.

Discov Oncol. 2025-5-30

[7]
TAMing Gliomas: Unraveling the Roles of Iba1 and CD163 in Glioblastoma.

Cancers (Basel). 2025-4-26

[8]
Emerging therapeutic strategies in glioblastsoma: drug repurposing, mechanisms of resistance, precision medicine, and technological innovations.

Clin Exp Med. 2025-4-13

[9]
Immune Cell Interplay in the Fight Against GBM.

Cancers (Basel). 2025-2-26

[10]
Emerging Approaches in Glioblastoma Treatment: Modulating the Extracellular Matrix Through Nanotechnology.

Pharmaceutics. 2025-1-21

本文引用的文献

[1]
Targeting the CXCR4/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression.

Signal Transduct Target Ther. 2017

[2]
The 2016 WHO classification of central nervous system tumors: what neurologists need to know.

Curr Opin Neurol. 2017-12

[3]
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.

J Immunother Cancer. 2017-7-18

[4]
An updated assessment of microglia depletion: current concepts and future directions.

Mol Brain. 2017-6-19

[5]
Development and Function of the Blood-Brain Barrier in the Context of Metabolic Control.

Front Neurosci. 2017-4-21

[6]
Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.

Brain. 2017-6-1

[7]
Cellular and Molecular Characterization of Microglia: A Unique Immune Cell Population.

Front Immunol. 2017-3-2

[8]
The Microenvironmental Landscape of Brain Tumors.

Cancer Cell. 2017-3-13

[9]
Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas.

PLoS One. 2017-2-24

[10]
The role of peripheral immune cells in the CNS in steady state and disease.

Nat Neurosci. 2017-1-16

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索